MiMARK Diagnostics

The company develops protein-based in vitro diagnostics for gynecological diseases using gynecological fluids as a sample source. Its GyLDa platform standardizes the handling of these samples to translate protein biomarker candidates into validated immunoassays and proprietary reagents. The technology aims to provide clinicians and healthcare systems with a minimally invasive alternative to traditional diagnostic methods for conditions such as endometrial cancer.